DORZOLAMIDE AND TIMOLOL EYE DROPS BP 5 MG
TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG · DIN 02489635 · HIKMA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is DORZOLAMIDE AND TIMOLOL EYE DROPS BP?
DORZOLAMIDE AND TIMOLOL EYE DROPS BP 5 MG contains TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02489635, held by HIKMA CANADA LIMITED, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled post market, status dated 24-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DORZOLAMIDE AND TIMOLOL EYE DROPS BP used for?
Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02489635 |
|---|---|
| Brand name | DORZOLAMIDE AND TIMOLOL EYE DROPS BP |
| Generic / active ingredient | TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG |
| Manufacturer | HIKMA CANADA LIMITED |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED51 TIMOLOL, COMBINATIONS |
| AHFS class | 52:40.12 ; 52:40.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 24-May-2022 |
| Original market date | 2020-05-01 00:00:00 |
How is it administered?
One drop in the affected eye(s) two times daily. If using other topical ophthalmic agents, administer at least ten minutes apart. Nasolacrimal occlusion reduces systemic absorption.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to section 11 of full monograph).
How is it supplied?
10 mL translucent, low-density polyethylene ophthalmic dispensers with a screw cap and dropper (fill volume of 5 mL per 10 mL bottle).
Contraindications
Hypersensitivity; reactive airway disease (asthma, COPD); sinus bradycardia, AV block, cardiac failure, shock; severe renal impairment (CrCl < 0.5 mL/s); use of oral carbonic anhydrase inhibitors.
Warnings and precautions
Systemic absorption may occur; risk of severe sulfonamide/beta-blocker reactions. Caution in cardiac failure, diabetes (masks hypoglycemia), and patients with corneal endothelial abnormalities.
What can be used instead?
Other Canadian products sharing ATC code S01ED51 TIMOLOL, COMBINATIONS. 21 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | DIN 02299615 |
| APO-TRAVOPROST-TIMOP PQ | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02415305 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02278251 |
| JAMP BRIMONIDINE/TIMOLOL | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02531704 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.